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Abstract
Proton NMR spectra of urine from subjects with multiple acyl-CoA dehydrogenase deficiency, caused by defects in
either the electron transport flavoprotein or electron transport flavoprotein ubiquinone oxidoreductase, provide a characteris-
tic and possibly diagnostic metabolite profile. The detection of dimethylglycine and sarcosine, intermediates in the oxidative
degradation of choline, should discriminate between multiple acyl-CoA dehydrogenase deficiency and related disorders
 .involving fatty acid oxidation. The excretion rates of betaine, dimethylglycine and sarcosine in these subjects give an
estimate of the minimum rates of both choline oxidation and methyl group release from betaine and reveal that the latter is
comparable with the calculated total body methyl requirement in the human infant even when choline intake is very low.
Our results provide a new insight into the rates of in vivo methylation in early human development. q 1998 Elsevier
Science B.V. All rights reserved.
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1. Introduction
The inherited disorder multiple acyl-CoA dehydro-
 .genase deficiency MADD has been characterised by
the accumulation of several short chain fatty acyl-CoA
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w xintermediates 1–3 . It is caused by a defect either in
 .the electron transfer flavoprotein ETF or electron
transfer flavoprotein ubiquinone oxidoreductase
 .ETFQO which are needed for the transfer of elec-
trons via FAD from these acyl-CoA compounds to
 . w xthe electron transport chain ETC 4,5 . The acyl-
CoA dehydrogenases affected include both those in-
volved with fatty acid oxidation and branched-chain
amino-acid catabolism.
Two neonatal onset forms of MADD have been
recognised. The first is associated with severe hypo-
glycaemia and metabolic acidosis and congenital ab-
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Fig. 1. Sites of inhibition of choline oxidation in multiple acyl-CoA dehydrogenase deficiency. Abbreviations: BADH, betaine aldehyde
dehydrogenase; BHMT, betaine-homocysteine methyl transferase; CDH, choline dehydrogenase; DMGDH, dimethylglycine dehydroge-
nase; GNM, glycine-N-methylase; SDH, sarcosine dehydrogenase; FMHT, 5-methyltetrahydrofolate-homocysteine methyltransferase;
5-CH –H folate, 5-methyltetrahydrofolate.3 4
normalities and presents during the first 24–48 h of
life. Infants in the second category do not have
congenital abnormalities, but also develop hypogly-
caemia and metabolic acidosis within the first few
w xdays of life 5 . A third, less severely affected cate-
w xgory, has a later, variable onset and age 5 .
Gas chromatographic and mass spectrometric
 .GC–MS analysis of urine from affected patients has
detected large increases in several short- and
medium-chain dicarboxylic acids and mono- and di-
w xcarboxylate glycine conjugates 6 . In this respect, the
GC–MS urinary profile shows some similarities to
that found in medium-chain acyl-CoA dehydrogenase
w xdeficiency 7 but differs appreciably with the addi-
tional detection of variable amounts of ethylmalonate,
glutarate, isovalerylglycine, iso- and n-butyrylgly-
cine, 2-methylbutyrylglycine and methylsuccinate.
Elevation of sarcosine in both urine and plasma
w xhas also been reported 2 . Two dehydrogenases which
mediate reactions of choline catabolism, dimethyl-
glycine dehydrogenase and sarcosine dehydrogenase
contain covalently bound FAD and also require ETF
w xand ETFQO for electron transfer to the ETC 8,9 .
Conversion of betaine to dimethylglycine is poten-
tially an important reaction in the transfer of methyl
 .groups to form methionine Fig. 1 , the precursor of
S-adenosyl methionine which is the ultimate methyl
donor for creatine formation and many other impor-
tant biological methylations. Choline oxidase activity
w xis highest in liver and kidney 10 and betaine homo-
cysteine methyl transferase activity is thought to be
w xconfined to these organs in Man 11 . However, the
quantitative significance of the choline oxidation
pathway in vivo is uncertain. A comparative study of
hepatic choline oxidase activity indicated that the
activity of the human enzyme, in adults, is very low
compared to several other mammalian species being
only one sixtieth that of the rat, which had the highest
w xactivity 12 of the species studied.
We have used proton nuclear magnetic resonance
1 .H-NMR spectroscopy to characterise a number of
disorders of organic acid and amino-acid metabolism,
and thereby provide a means for their rapid diagnosis,
by exploiting the unique ability of the technique to
 .select C–H n containing metabolites irrespective of
w xcharge 13–15 . The technique is particularly applica-
ble to the detection of intermediates in the choline
oxidation pathway, e.g., betaine, dimethylglycine and
 .sarcosine Fig. 1 . We have applied the technique to
investigate the abnormal metabolites in urine from
three patients who were diagnosed with MADD in
order to investigate the flux through the choline
 .oxidation pathway and simultaneously determine
whether the NMR spectrum itself was diagnostic for
the disorder. A preliminary report was made on a
w xsample from one of these patients 16 .
2. Materials and methods
2.1. Patients
Patient 1 is a boy who presented at the age of 8
months with fits and hepatomegaly. At the time of
 .sampling 2 weeks later he was still unwell, receiv-
ing glucose and saline only and therefore, negligible
dietary choline. He was unresponsive to riboflavin
but subsequently, he recovered rapidly and has been
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maintained subsequently on a normal diet with atten-
tion given to regular feeding to avoid hypoglycaemia
and consequent stimulation of fatty acid and protein
catabolism. He is now 8 years old and is well having
developed normally. Patient 2 was a girl who pre-
sented at the age of 24 h with severe compensated
metabolic acidosis after an uneventful birth. She was
given D,L-carnitine orally from day 2 3=100 mg
y1 y1.kg day , stabilised with intravenous glucose and
sodium bicarbonate, then maintained on a diet with a
reduced fat intake and discharged at 7 weeks. At the
 .time of sampling 4 weeks , her condition was rela-
tively stable. She was still receiving oral carnitine
and a fat free diet containing protein and carbo-
hydrate. Her rate of growth was 4.5 g kg body
.y1 y1 weight day mean for healthy babies approx. 7
.g . The choline intake of Patient 2 was also negligible
at the time of study. She was re-admitted to hospital
at 4 months and died at the age of 4.5 months. Patient
3 is a girl aged 11.5 years with a mild form of the
disorder and has been receiving a protein reduced
diet with regular meals. None of the patients had
congenital abnormalities. All diagnoses were made
initially by GC–MS and confirmed when possible by
the detection of CO from oxidation of fatty acids of2
various chain lengths and leucine using cultured skin
fibroblasts.
2.2. Samples
Random urine samples were analysed which had
either been taken for diagnosis or therapeutic moni-
toring.
2.3. NMR spectroscopy
For 1H-NMR spectroscopy urine samples were
prepared as follows: 0.5 ml of urine was transferred
to a 5-mm outer diameter NMR tube Goss Instru-
.ments, Ingatestone, Essex, UK and 50 ml of 20-mM
 .sodium—2,2,3,3 trimethylsilyl tetradeutero-pro-
 . 2  .pionate B.D.H., Poole, Dorset, UK in H O Goss2
was added to act as a chemical shift reference, quan-
tification standard and a spectrometer lock. Normal
 . Fig. 2. Proton NMR spectrum 500 MHz of a sample of urine from a 3-month-old healthy girl. The spectrum is of 128 transients 11
.min . Ac: acetate; Ala: alanine; Bt: betaine; Cit: citrate; Cr: creatine; Crn: creatinine; Dma: dimethylamine; Dmg: dimethylglycine; Gly:
glycine; Lac: lactate. For more details of assignments, see text.
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 .one dimensional 1D spectra were collected for each
urine sample. Spectra were recorded either on a Jeol
GSX 500 MHz or a Bruker AM600 MHz spectrome-
ter with a 30–458 excitation pulse, an acquisition
time of 1.7 s, a sweep width of 12 ppm, and a
 .recycling time of 5 s. Solvent H O suppression was2
performed using pre-saturation of the water reso-
nance with a 2-s irradiation pulse of 0.2 W prior to
excitation and acquisition. Some samples were then
re-run using a Hahn spin-echo pulse sequence 908-
.t–1808-t-acquire with a pulse recycle time of 2 s
and inter-pulse delay, ts60 ms. This ensured that
even-numbered and odd-numbered multiplets differed
in phase by 1808.
Peak assignments were made as previously de-
w xscribed 13–15 . In summary, where available, au-
thentic standards were run under the same conditions
as the urine samples. Some standards were also run
after varying the pH over a range which included the
urine pH values. Hahn spin-echo spectra aided spec-
tral interpretation by inverting even-numbered multi-
plets. In addition, a spectrum using two dimensional
 .correlated spectroscopy COSY was recorded on the
urine sample from Patient 1 to aid signal assignments
by detecting through bond couplings. The 2D spec-
trum was recorded at 500 MHz with a sweep width
of 9 ppm, an SIs2 k, with 512 2nd dimensional
time increments, an acquisition time of 0.3 s and
 .Fig. 3. Proton NMR spectrum 500 MHz of a sample of urine from an 8-month-old boy with multiple acyl-CoA dehydrogenase
 .deficiency. The spectrum is of 128 transients 11 min . Ag: glycyl CH of various short and medium chain acylglycines; Bg:2
butyrylglycine; Dca: dicarboxylic acids and hexanoyl- plus suberyl-glycine; Etm: ethylmalonate; Gt: glutarate; Hg: hexanoylglycine; Ibg:
isobutyrylglycine; Ivg: isovalerylglycine; Sc: sarcosine; Sg: suberylglycine. For other assignments, see Fig. 2, and for more details of
assignments, see text.
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recorded in the magnitude mode with two 908 pulses.
Peak heights were used to quantify metabolites. As
creatinine concentration can be determined directly
from the NMR spectrum, metabolite excretion rates
were expressed as a peak height ratio to creatinine.
However, in infants and older children, creatine ex-
 .cretion Fig. 2 is substantial and so, metabolite
concentrations relative to the sum of creatinine plus
w xcreatine were also measured 17 .
3. Results
Fig. 2 shows a 1H-NMR spectrum of urine from a
healthy 3-month-old child. The most prominent sig-
nals are from the methyl protons of betaine, creatine
and creatinine. Betaine excretion is very high in
neonates and infants reaching a maximum at 2–3
months after birth, but is normally undetectable by
1H-NMR spectroscopy in adult urine analysed under
w xthe same conditions 18,19 . In a group of healthy
infants and children, we have found that urinary
dimethylglycine is -0.10 mol moly1 creatinine in
the early neonatal period, rising to a peak of up to
y1  y10.16 mol mol at 2–3 months 0.14 mol mol in
.the subject whose spectrum is shown in Fig. 2 ,
falling to -0.05 by 10 years, whereas sarcosine is
-0.03 mol moly1 creatinine throughout and often
too small to assign unambiguously Davies, Holmes,
.Chalmers, Iles, unpublished .
The spectrum from Patient 1 is shown in Fig. 3.
Two overlapping triplets at 0.84 and 0.88 ppm are
assigned to the methyl groups of hexanoylglycine and
ethylmalonate, respectively. Signals from the methyl
 .groups of isovalerylglycine 0.94 ppm and isobu-
 .tyrylglycine 1.12 ppm can be identified. Reso-
nances from the methylene groups of the dicarboxyl-
ates adipate, sebacate and suberate overlap at 1.30
 .not adipate , 1.54–1.56 and 2.18–2.21 ppm together
with methylene resonances from suberylglycine and
hexanoylglycine at 1.3, 1.6 and 2.2 ppm which have
an additional signal at 2.30 ppm. Neither n-
butyrylglycine or 2-methylbutyrylglycine could be
detected in the 1-D spectrum and the COSY spectrum
did not contain the expected cross-peaks so their
 .concentration must have been very low -50 mM . Ta
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Glutarate was confirmed from a characteristic cross
peak in the 2-D spectrum and singlets at 2.74 N-
.  .methyl and 3.62 ppm methylene may be assigned
to sarcosine. Prominent resonances at 2.92 N-di-
.  .methyl and 3.73 ppm methylene are from dimeth-
ylglycine, which is the largest component. The spec-
 .trum from Patient 2 not shown revealed both
dimethylglycine and much larger sarcosine reso-
 .nances Table 1 but apart from glutarate signals
other dicarboxylates were barely detectable. The
spectrum of Patient 3 showed the presence of both
sarcosine and dimethylglycine. However, only small
signals were visible from adipate, sebacate and suber-
ate and the other dicarboxylates and glycine conju-
gates were undetectable. Betaine aldehyde, an inter-
 .mediate in choline conversion to betaine Fig. 1 was
below NMR detection limits in all spectra.
Table 1 shows the rates of excretion of metabolites
associated with the choline oxidation pathway rela-
 .tive to creatinine qcreatine excretion for the three
patients. The accumulated sum of metabolites distal
to the choline dehydrogenase step, i.e., the sum of
betaine, dimethylglycine and sarcosine excretion is a
measure of the rate of choline oxidation assuming
negligible sarcosine synthesis from glycine N-meth-
 w x .ylation Ref. 20 ; discussion below , which is proba-
bly an underestimate as the inhibition of sarcosine
dehydrogenase is unlikely to be 100% especially in
Patients 2 and 3 who were clinically mildly affected
at the time of study. Similarly, the sum of dimethyl-
glycine and sarcosine excretion is equivalent to the
 .  .minimum rate of betaine re methylation of homo-
cysteine.
4. Discussion
The 1H-NMR urine spectra of these patients
showed some superficial similarities to those from
patients with medium chain acyl-CoA dehydrogenase
w xdeficiency 21 . This phenomenon occurs because
both disorders result in the accumulation of abnormal
amounts of medium-chain fatty acyl-CoA esters which
are subsequently converted to dicarboxylates from v
and vy1 oxidation. However, there is a major
difference in that signals from both sarcosine and
especially dimethylglycine are present in the MADD
spectra in addition to the short-chain fatty acyl-
glycines. Increased dimethylglycine has not previ-
ously been identified in this disorder, apart from our
w xpreliminary study 16 , although presumably it accu-
mulates because of the lack of ETF or ETFQO for
electron transfer and consequent inhibition of dimeth-
ylglycine dehydrogenase activity. Our findings
demonstrate that it may be one of the major abnormal
metabolites excreted in this disorder even when the
defect is relatively minor as appears to be the case in
Patient 3. Thus, we conclude that the 1H NMR
spectrum may be diagnostic for this disorder.
We have shown previously that neonates excrete
w xsignificant amounts of betaine in their urine 18,19 .
It is perhaps surprising that the betainercreatinine
ratio in these patients is not abnormal, lying within
range of the values we have found for healthy
w xneonates and infants 19 . This suggests that although
dimethylglycine accumulates, betaine to dimethyl-
glycine conversion via betaine homocysteine methyl
transferase is relatively unaffected.
Because dimethylglycine arises from the transfer
of a methyl group from betaine to homocysteine to
form methionine, its excretion rate plus that of sarco-
sine gives a measurement of the rate of methylation
 .from this reaction Fig. 1 . Methionine in the form of
 .S-adenosyl methionine SAM is the prime methyl
donor for methyl-group transfers, the majority of
which are used for creatine synthesis, at least in the
w xadult 20,22 . In a growing child, the rate of creatine
synthesis is in effect equivalent to the rate of the sum
of creatinine plus creatine excretion plus the amount
of creatine incorporated into the body in muscle cells
as free creatine and phosphocreatine as a result of the
w xgain in muscle mass 19 . We have calculated that the
increase in muscle creatine content is approximately
20% of the total synthesised in a 1-month-old child
w x19 and probably less than in Patient 2, whose
growth rate was slow, and only 3% in a healthy
8-month-old child. We have previously considered
also the quantitatively important requirement for
methyl groups in the synthesis of phosphatidylcholine
w xfrom phosphatidylethanolamine 19 which could, in
theory, reach the equivalent of 60% of the demand
for creatine synthesis. However, in the healthy indi-
vidual, much of this requirement may be obviated by
the synthesis of phosphatidylcholine via the CDP-
 .choline pathway from dietary choline itself, al-
though this is clearly not the case in Patients 1 and 2
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who were receiving minimal choline in their diet at
the time of study.
The other major source of methyl groups for the
w xbody is from dietary methionine. Krebs et al. 22
calculated that the rate of creatine synthesis, in effect
 .equivalent to the rate of creatinine qcreatine excre-
w xtion 19 , is equivalent to the dietary methionine
intake. We have estimated that in the neonatal period
in a healthy infant, nearly all of the methyl groups
provided by the methionine intake would be ac-
 .counted for by the methionine requirement for net
wprotein synthesis and accumulation of muscle crea-
x  .tine Holmes, Snodgrass, Iles, unpublished with
little or none to spare for the balance of creatine
synthesis. The methylation of guanidinoacetate to
form creatine is almost entirely restricted to the liver
w xand pancreas 23 . Therefore, the excretion rate of
w x wdimethylglycineqsarcosine relative to creatinine
xqcreatine is a reasonable measure of the activity of
 .betaine homocysteine methyl transferase BHMT
relative to methylation in vivo in respect of the
requirement for steady state creatine synthesis. Sur-
prisingly, the magnitude of the BHMT flux in the
neonatal period suggests that this process could make
 .a major net contribution to the total body require-
ment for methyl groups if the choline precursor were
supplied exogenously.
 .The alternative reaction for re methylation of
homocysteine is mediated by the enzyme 5-methylte-
trahydrofolate homocysteine methyl transferase
 .FHMT , the methyl group being provided by 5-
 .methyltetrahydrofolate Fig. 1 . The relative contribu-
tions of the two pathways for homocysteine methyla-
tion have not yet been determined although the sig-
nificance of the folate methylating system has been
repeatedly emphasised, particularly as the FHMT en-
w xzyme is more widely distributed 24,25 . The FHMT
process is presumably of particular importance in
those issues that do not possess BHMT, e.g., brain.
5-Methyltetrahydrofolate is made from methylene-te-
trahydrofolate. The methylene moiety can arise from
serine but is also produced from the demethylation of
dimethylglycine and sarcosine, reactions that are lim-
ited in MADD. Thus, our data present a paradox
whereby choline oxidase activity appears to be high
in the presence of low choline intake and irrespective
of protein intake. In order to account for this situa-
tion, as no other precursor of betaine is known apart
from betaine itself, we suggest that body endogenous
stores of choline phospholipid are degraded. It is
possible that a methyl group deficit is present in
severe cases which might account for the demyelina-
tion observed in MRI studies of some patients with
w xMADD 26 as phosphatidylcholine and sphingo-
myelin are degraded by phospholipases to provide
choline.
The rate of methyl group release based on the
estimated rate of dimethylglycine plus sarcosine ex-
 .cretion Table 1 in the youngest subject, Patient 2, is
over three times that of the methyl group requirement
accounted for by creatinineqcreatine excretion. That
the rate of excretion of dimethylglycine and sarcosine
in Patient 2 was almost twice as great as that for
Patient 1 may be related to the more severe expres-
sion of the disorder in the girl and also possibly
reflect the greater flux in this pathway and require-
ment for SAM in the neonatal and early infant period
w x27 . There is no indication that flux through the
betaine demethylation pathway should be any faster
in patients with MADD than in healthy children.
Indeed, with virtually no choline intake, it might be
expected that the flux would be decreased. Therefore,
if these results can be extrapolated to apply to the
normal infant, then the rate of methyl group release
via the betaine homocysteine methyl transferase route
would seem to be far above the total daily require-
w xment for methyl groups, in the neonatal period 18,19 .
In addition, as discussed above, further metabolism
of dimethylglycine via sarcosine and glycine gener-
w xates one-carbon fragments 28 which can, at least
theoretically, also be recovered as methyl groups
although incorporation into serine may be their im-
w xmediate fate 28 . Patient 1, at the age of 8 years, is
still excreting DMGqsarcosine at approx. 0.9 mol
moly1 creatinine even though he has been asymp-
tomatic since this episode, eating a normal diet and
continuing to thrive. Some additional evidence that
this extrapolation can be made to healthy subjects is
provided by a 7-week-old child we have recently
studied who was excreting DMG at over 1 mol
y1 w xmol creatinine q creatine . He was clinically
 .asymptomatic and had a normal formula feed diet
growing at the 95th percentile Holmes, Snodgrass,
.Iles, unpublished . Furthermore, premature babies
have a greater need for methyl groups in the early
postnatal period than full-term infants yet excrete
( )S.P. Burns et al.rBiochimica et Biophysica Acta 1406 1998 274–282 281
betaine at comparable rates to the latter group in spite
w xof receiving very little choline in this period 29,30 .
w xMudd et al. 20 studied sarcosine excretion in two
patients aged 15 and 16 with sarcosinaemia sarco-
.sine dehydrogenase deficiency . Dimethylglycine was
not estimated. The level of methionine and choline in
the diet was varied in order to calculate what the
contribution of each of these methyl donors was to
the methyl supply as measured by creatinine, creatine
and sarcosine excretion. At no time did the sarcosine
excretion exceed the creatine and creatinine excre-
tion. However, with excess methionine or choline
intake, the sum of methionine and choline intake was
greater than the creatine and creatinine excretion, but
not the sum of creatine and creatinine and sarcosine.
Interestingly, at all levels of choline intake, sarcosine
production equalled or exceeded choline intake and
Mudd et al. concluded that methionine had to be used
for sarcosine synthesis. However, when methionine
intake was increased, an almost equimolar increase in
sarcosine excretion occurred. Given that three
molecules of methionine are needed for each choline
molecule synthesized, it is likely, as concluded by
Mudd et al., that this sarcosine was generated by
direct methylation of glycine by SAM which would
seem a feasible route when methyl groups are sup-
plied in excess. In our study, methylation of glycine
is likely to be minimal since the supply of dietary
methyl groups from both methionine and choline was
clearly inadequate for Patient 1 and from choline
insufficient for Patient 2. Patient 3 received a low
 .protein methionine intake. Mudd et al. concluded
that the rate of sarcosine formation from choline was
never more than 20% of the rate of creatinine synthe-
sis. Our results suggest that in the neonate and young
infant, the rate may be higher. Even if all the urinary
sarcosine was produced from glycine N-methylation,
the capacity of methyl group transfer via betaine
reflected in the excretion of dimethylglycine would
still exceed the methylation requirement for creatine
synthesis by over 60% in Patient 2 and 66% of the
requirement in Patient 1.
It appears therefore, that the capacity of the human
choline oxidase system in vivo may be greater than
has been previously realised and that choline may
play a major role in the transfer, and perhaps provi-
sion, of methyl groups and other one-carbon units in
the human infant.
In conclusion, it is not clear why choline oxidation
appears to be highly active in the neonatal period
regardless of the dietary choline supply. These results
may therefore have major consequences for choline
and methionine provision in the neonatal period.
Inadequate intake of one or both could lead to the
degradation of endogenous phosphatidylcholine and
sphingomyelin to provide choline substrate, which is
clearly deleterious to development.
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